Neurometrix Inc (NURO)

$4.05 +0.12 (3.05%)
Market Cap 8.27M
Revenue (ttm) 5.90M
Net Income (ttm) -6.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -110.68%
Debt to Equity Ratio 0.00
Volume 1,500
Avg Vol 20,524
Day's Range N/A - N/A
Shares Out 2.04M
Stochastic %K 64%
Beta 2.20
Analysts Strong Buy
Price Target $50.00

Latest News on NURO

NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO

Jan 6, 2025, 6:34 PM EST - 12 days ago

NEUROMETRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NeuroMetrix, Inc. - NURO

NeuroMetrix to be Acquired by electroCore

Dec 17, 2024, 4:05 PM EST - 4 weeks ago

NeuroMetrix to be Acquired by electroCore

NeuroMetrix Reiterates its Review of Strategic Alternatives

Aug 13, 2024, 2:47 PM EDT - 5 months ago

NeuroMetrix Reiterates its Review of Strategic Alternatives

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:33 AM EDT - 5 months ago

NeuroMetrix, Inc. (NURO) Q2 2024 Earnings Call Transcript

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

Jul 31, 2024, 2:03 PM EDT - 6 months ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2024 Business Highlights Conference Call

NeuroMetrix Reports Q1 2024 Business Highlights

May 15, 2024, 4:00 PM EDT - 8 months ago

NeuroMetrix Reports Q1 2024 Business Highlights

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

Apr 19, 2024, 8:00 AM EDT - 9 months ago

NeuroMetrix Announces Steps Taken to Enhance Shareholder Value

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

Mar 14, 2024, 9:00 AM EDT - 11 months ago

NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Mar 13, 2024, 9:00 AM EDT - 11 months ago

NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® Fibromyalgia

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Mar 12, 2024, 8:00 AM EDT - 11 months ago

Echo Lake Capital Issues Top Ten List of Reasons Why Shai Gozani, CEO of Neurometrix Inc., Should Be Fired

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

Mar 4, 2024, 8:00 AM EST - 11 months ago

Echo Lake Capital Calls for the Liquidation of Neurometrix, Inc.

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 11:55 AM EST - 11 months ago

NeuroMetrix, Inc. (NURO) Q4 2023 Earnings Call Transcript

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

Feb 22, 2024, 7:00 AM EST - 11 months ago

NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

Feb 15, 2024, 9:00 AM EST - 1 year ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

Feb 13, 2024, 9:00 AM EST - 1 year ago

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

Jan 8, 2024, 9:43 AM EST - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on January 10, 2024

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

Dec 12, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

Dec 5, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix Announces One-for-Eight Reverse Stock Split

Nov 20, 2023, 9:00 AM EST - 1 year ago

NeuroMetrix Announces One-for-Eight Reverse Stock Split

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

Oct 30, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on November 1, 2023

NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript

Oct 27, 2023, 10:22 AM EDT - 1 year ago

NeuroMetrix Inc. (NURO) Q3 2023 Earnings Call Transcript

NeuroMetrix Reports Q3 2023 Business Highlights

Oct 26, 2023, 7:00 AM EDT - 1 year ago

NeuroMetrix Reports Q3 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

Oct 23, 2023, 11:13 AM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

Oct 2, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

Sep 28, 2023, 12:19 PM EDT - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on October 4, 2023

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

Aug 30, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023

NeuroMetrix Reports Q2 2023 Business Highlights

Jul 27, 2023, 7:00 AM EDT - 1 year ago

NeuroMetrix Reports Q2 2023 Business Highlights

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

Jul 20, 2023, 1:00 PM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

Jul 11, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

Jun 28, 2023, 9:00 AM EDT - 1 year ago

Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

Jun 7, 2023, 9:00 AM EDT - 1 year ago

Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

May 31, 2023, 9:00 AM EDT - 1 year ago

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript

May 3, 2023, 12:41 PM EDT - 1 year ago

NeuroMetrix, Inc. (NURO) Q1 2023 Earnings Call Transcript

NeuroMetrix Reports Q1 2023 Financial Results

May 3, 2023, 7:00 AM EDT - 1 year ago

NeuroMetrix Reports Q1 2023 Financial Results

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

Apr 28, 2023, 9:21 AM EDT - 1 year ago

NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

Mar 21, 2023, 9:00 AM EDT - 1 year ago

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript

Feb 23, 2023, 5:23 PM EST - 2 years ago

NeuroMetrix, Inc. (NURO) Q4 2022 Earnings Call Transcript

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

Feb 23, 2023, 7:00 AM EST - 2 years ago

NeuroMetrix Reports Q4 and Full Year 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

Feb 16, 2023, 2:58 PM EST - 2 years ago

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Jan 23, 2023, 9:00 AM EST - 2 years ago

NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

Nov 8, 2022, 9:00 AM EST - 2 years ago

NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript

Oct 20, 2022, 9:32 AM EDT - 2 years ago

NeuroMetrix, Inc. (NURO) Q3 2022 Earnings Call Transcript

NeuroMetrix Reports Q3 2022 Financial Results

Oct 20, 2022, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q3 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

Oct 12, 2022, 3:47 PM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

Sep 23, 2022, 10:13 AM EDT - 2 years ago

NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

Sep 1, 2022, 9:00 AM EDT - 2 years ago

NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript

Jul 21, 2022, 11:14 AM EDT - 2 years ago

NeuroMetrix, Inc. (NURO) CEO Shai Gozani on Q2 2022 Results - Earnings Call Transcript

NeuroMetrix Reports Q2 2022 Financial Results

Jul 21, 2022, 7:00 AM EDT - 2 years ago

NeuroMetrix Reports Q2 2022 Financial Results

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

Jul 14, 2022, 11:32 AM EDT - 2 years ago

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call